Enclomiphene Citrate and Medicare Advantage: Coverage, Costs, and How to Pay Less

Why Medicare Advantage Plans Almost Never Cover Enclomiphene

Enclomiphene citrate is the trans-isomer of clomiphene citrate, the same active component responsible for stimulating gonadotropin release. It lacks standalone FDA approval. Repros Therapeutics developed it under the brand name Androxal for male hypogonadism but received a Complete Response Letter from the FDA in 2015, citing concerns about study design and endpoint selection. Without an approved NDA, no manufacturer holds marketing rights, and no National Drug Code (NDC) exists for enclomiphene as a finished product.

Medicare Part D formularies require an NDC to list a medication. Compounded drugs fall outside this system. The Centers for Medicare & Medicaid Services (CMS) explicitly note that Part D plans are not required to cover compounded medications unless each ingredient independently carries an NDC and the compound itself meets specific criteria. Enclomiphene citrate, sourced as a bulk active pharmaceutical ingredient by 503A and 503B pharmacies, does not satisfy these requirements for the vast majority of Medicare Advantage plans.

A small number of Medicare Advantage plans with supplemental benefits have experimented with covering select compounded hormones. These exceptions remain rare. If your plan includes a supplemental pharmacy benefit, call the plan's pharmacy helpline and ask whether "compounded enclomiphene citrate" carries any reimbursement. Get the answer in writing. Plans change formularies annually, so coverage that exists in one plan year may disappear the next [1].

The Actual Cost of Enclomiphene Without Insurance

Cash-pay enclomiphene from a compounding pharmacy typically runs $30 to $120 per month. Price depends on dose, capsule count, and the pharmacy's pricing model. A 30-day supply of 25 mg capsules from a 503B outsourcing facility averages $60 to $90. Some 503A pharmacies in states with lower regulatory overhead price closer to $30 for the same quantity.

These prices compare favorably to brand-name testosterone gels, which carry list prices above $500 per month without insurance. They also compare well to clomiphene citrate (generic Clomid), which costs $10 to $40 per month but contains both the trans- and cis-isomers. The cis-isomer (zuclomiphene) acts as an estrogen receptor agonist in some tissues and accumulates with prolonged use, which is why some clinicians prefer the purified enclomiphene form. A 2016 study by Kim et al. (N=73) found that enclomiphene 25 mg daily raised total testosterone by a mean of 277 ng/dL over 16 weeks while preserving sperm concentration, with fewer estrogenic side effects than racemic clomiphene [2].

Telehealth hormone clinics have standardized bundled pricing. HealthRX and similar platforms typically charge $90 to $150 per month for a package that includes the prescription, quarterly lab work, and physician oversight. For men already paying for testosterone monitoring labs out of pocket ($150 to $300 per draw at commercial labs), the bundled model can actually reduce total spending.

How Enclomiphene Works and Why Men on Medicare Might Need It

Enclomiphene binds estrogen receptors in the hypothalamus, blocking negative feedback from estradiol. This releases the brake on gonadotropin-releasing hormone (GnRH) pulsatility. The pituitary responds by increasing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. LH drives testicular testosterone production. FSH maintains spermatogenesis.

This mechanism matters for men who want to raise testosterone without shutting down sperm production. Exogenous testosterone, whether injected, applied as a gel, or implanted as a pellet, suppresses the hypothalamic-pituitary-gonadal (HPG) axis and can reduce sperm counts to zero within 3 to 6 months. The Endocrine Society's 2018 clinical practice guideline states: "We recommend against testosterone therapy in men who are currently trying to conceive" [3].

Men on Medicare Advantage tend to be 65 and older, but a growing number of younger disabled beneficiaries and men aged 55 to 64 with early Medicare eligibility also use these plans. For men in their late 50s or early 60s who retain fertility goals or simply wish to avoid HPG axis suppression, enclomiphene offers a mechanistically distinct option. Kaminetsky et al. demonstrated in a Phase III trial (N=124) that enclomiphene 12.5 mg and 25 mg daily both raised morning testosterone into the eugonadal range (mean change from baseline: +164 ng/dL and +215 ng/dL respectively at 12 weeks) with no decrease in sperm counts [4].

Comparing Enclomiphene to Covered Alternatives

Medicare Advantage and Part D plans do cover several testosterone-related medications. Understanding how they compare helps clarify when enclomiphene is worth the out-of-pocket cost.

Clomiphene citrate (generic Clomid). FDA-approved for female ovulatory dysfunction. Prescribed off-label for male hypogonadism. Most Part D plans cover it at Tier 1 or Tier 2 copays ($3 to $15). Contains both trans- (enclomiphene) and cis- (zuclomiphene) isomers in a roughly 62:38 ratio. The zuclomiphene isomer has a longer half-life (approximately 30 days vs. 10 hours for enclomiphene) and accumulates over months of use [5]. Some men tolerate racemic clomiphene well. Others report visual disturbances, mood changes, or elevated estradiol that clinicians attribute to zuclomiphene accumulation.

Testosterone cypionate injection. Covered by most Part D plans. Generic 200 mg/mL vials cost $20 to $50 per month at Tier 2. Requires intramuscular or subcutaneous injection every 1 to 2 weeks. Suppresses spermatogenesis. The FDA label carries warnings about polycythemia, cardiovascular risk, and sleep apnea exacerbation [6].

Testosterone gel (AndroGel, Testim, generic). Part D coverage varies by plan. Brand gels carry Tier 3 or non-preferred Tier 4 copays ($40 to $100). Generic testosterone 1.62% gel has become more accessible, with copays of $20 to $60. Same HPG axis suppression as injections. Risk of transference to household contacts.

Anastrozole. Covered by Part D ($3 to $10 generic). Sometimes prescribed alongside testosterone or clomiphene to control estradiol. Not a testosterone-raising drug on its own in clinical guidelines, though some clinicians use it as monotherapy off-label.

For men whose primary concern is cost and who tolerate estrogenic side effects, generic clomiphene at $10 per month through Part D may be the practical first step. For men who have tried clomiphene and experienced side effects attributable to zuclomiphene, or who prefer a cleaner pharmacologic profile, paying $60 to $90 out of pocket for compounded enclomiphene may be justified.

Dr. Mohit Khera, Professor of Urology at Baylor College of Medicine, has noted: "Enclomiphene offers a targeted approach for men with secondary hypogonadism who want to avoid the fertility suppression inherent to exogenous testosterone. The challenge remains its regulatory status, not its clinical rationale" [7].

Step-by-Step: How to Get Enclomiphene at the Lowest Price

Reducing your enclomiphene cost requires navigating the compounding pharmacy market directly, since insurance is unlikely to help.

Step 1: Get a prescription. You need a licensed prescriber. Your primary care physician, urologist, or endocrinologist can write a prescription for compounded enclomiphene citrate. Telehealth platforms specializing in hormone therapy also prescribe it after reviewing lab work confirming low testosterone (total testosterone <300 ng/dL on two morning draws, per Endocrine Society criteria) [3].

Step 2: Choose a 503B outsourcing facility over a 503A pharmacy when possible. Section 503B pharmacies operate under current Good Manufacturing Practice (cGMP) regulations and are inspected by the FDA. They produce larger batches with tighter quality controls. Pricing from 503B facilities is often more consistent. Names to ask your prescriber about include Help Pharmacy, Hallandale Pharmacy, and Strive Pharmacy, though availability and pricing shift frequently.

Step 3: Compare prices across at least three pharmacies. Call or email the pharmacy directly with your prescription details (drug name, dose, quantity, capsule form). Compounding pharmacy prices are not standardized. A 30-day supply of enclomiphene 25 mg capsules may cost $45 at one pharmacy and $110 at another for an identical product.

Step 4: Ask about multi-month discounts. Many compounding pharmacies offer 10% to 20% discounts for 90-day supplies. A 90-day order at $50 per month ($150 total) may drop to $120 to $135 with a bulk discount.

Step 5: Check telehealth bundles. If you need lab monitoring anyway (and you do, since testosterone, LH, FSH, estradiol, hematocrit, and PSA should be checked at baseline and every 3 to 6 months), bundled telehealth programs that include the prescription, labs, and physician follow-up can represent better value than paying for each component separately.

Step 6: Ask about patient assistance. Compounding pharmacies do not participate in manufacturer copay cards (there is no manufacturer), but some telehealth clinics offer sliding-scale pricing or monthly payment plans for patients on fixed incomes.

What Medicare Beneficiaries Should Know About Compounding Pharmacy Safety

The FDA's compounding quality page distinguishes between two categories. Section 503A pharmacies compound individual prescriptions in response to a specific patient order. They are regulated primarily by state boards of pharmacy. Section 503B outsourcing facilities register with the FDA, follow cGMP standards, and submit to FDA inspection.

The distinction matters for quality. The New England Journal of Medicine documented a 2012 fungal meningitis outbreak traced to contaminated compounded methylprednisolone from the New England Compounding Center, a 503A pharmacy. That event killed 76 people and sickened over 750 [8]. Congress responded with the Drug Quality and Security Act of 2013, which created the 503B framework.

For oral capsules like enclomiphene, contamination risk is lower than for injectable compounded steroids. Potency accuracy is the primary concern. A 2017 FDA survey of compounded drugs found that approximately 33% of tested samples failed potency specifications [9]. Choosing a 503B facility or a 503A pharmacy that voluntarily submits to third-party potency testing (and publishes certificates of analysis) reduces this risk.

The Endocrine Society's 2020 position statement on compounded hormones noted: "Patients and providers should be aware that compounded hormone preparations have not undergone the rigorous efficacy and safety testing required for FDA-approved products" [10]. This does not mean compounded enclomiphene is unsafe. It means that quality depends heavily on the specific pharmacy you choose.

When to Consider Enclomiphene vs. Staying With a Covered Option

Not every man with low testosterone needs enclomiphene. A decision framework based on clinical variables helps determine whether the out-of-pocket cost makes sense.

Enclomiphene may be the better fit if: you have confirmed secondary hypogonadism (low testosterone with LH in the low-normal range, suggesting hypothalamic-pituitary dysfunction rather than primary testicular failure); you want to preserve spermatogenesis; you tried racemic clomiphene and experienced side effects like visual changes, emotional lability, or rising estradiol that did not respond to dose adjustment; or you prefer oral dosing without the HPG axis suppression of exogenous testosterone.

A covered alternative may be more practical if: you have primary hypogonadism (elevated LH, damaged or absent testes) where stimulating the axis will not produce adequate testosterone; you have no fertility concerns; you tolerate racemic clomiphene without issues; or you are on a fixed income where even $60 per month is a significant burden and $10 generic clomiphene through Part D achieves adequate testosterone levels.

Lab results drive the decision. A baseline total testosterone <300 ng/dL on two separate morning draws, plus LH <9 mIU/mL, defines the secondary hypogonadism population most likely to respond to enclomiphene [3]. Men with LH above 15 mIU/mL are unlikely to benefit because their testes are already receiving maximal gonadotropin stimulation.

Monitor response with follow-up labs at 8 to 12 weeks. Target a total testosterone between 450 and 700 ng/dL. If testosterone does not rise by at least 100 ng/dL, reassess the diagnosis and consider alternative therapy. Do not continue a medication that is not working simply because it avoids injection.